Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Shengtai Pharma Seeks Global Growth
- ChinaBio Today submits: Shengtai Pharmaceutical, Inc. (SGTI.OB) will begin a push to sell its pharmaceutical grade glucose products internationally. To get this done, the company has restructured its international sales team. The company said it already has customers in 70 countries, but according to SEC documents, Shengtai...
- External links 2008-10-31
- China Pharma Gets Green Light for Antibiotics Trial
- ChinaBio Today submits: China Pharma Holdings (CPHI.OB) was given the go-ahead by the SFDA to begin clinical trials of a novel antibiotic combination formula. China Pharma describes the new product as a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor. Its clinical trial will begin in November. ...
- External links 2008-10-30
- American Oriental Announces Two Acquisitions
- ChinaBio Today submits: American Oriental Bioengineering, Inc. AOB completed two acquisitions while, at the same time, announcing it had declined to pursue a third. In August, AOB had announced a signed letter of intent to pay $110 million to acquire an unnamed China pharmaceutical distributor with $550 million in...
- External links 2008-10-23
- China Biologic Buys Another Plasma-Based Pharma
- ChinaBio Today submits: China Biologic Products, Inc. (CBPO.OB) continued its acquisitive path by announcing its intention to purchase a 35% stake in Xi'an Huitian Blood Products Co., Ltd. Both company manufacture plasma-based pharmaceuticals. China Biologic will pay 44 million RMB ($6.4 million) for the purchase of Huitian, the only...
- External links 2008-10-17
- Investors Liked What They Saw in Simcere's Q3 Report
- ChinaBio Today submits: Simcere Pharmaceutical Group SCR released very positive unaudited financial results for its third quarter. At the same time, the company said it would begin a $50 million share buyback. At the end of the quarter, Simcere reported cash and short-term investments of 831 million RMB ($122.4...
- External links 2008-11-06
- Shengtai Pharma Considers Business Disruptions Temporary
- ChinaBio Today submits: Shengtai Pharmaceutical, Inc. (SGTI.OB) reported that the August Olympics caused a slowdown in its fiscal year 2009 Q1 (ended September 30, 2008) financial performance. The government restrictions on manufacturing and transportation, put in place in Beijing to reduce pollution, disrupted normal business activity. As a result,...
- External links 2008-11-16
- China Pharma Reports Improved Q3, Accounts Receivable Also Up
- ChinaBio Today submits: China Pharma Holdings (CPHI.OB) reported its Q3 revenues climbed 52% to $12.61 million and net income was up 38% to $4.25 million, which equates to 10 cents per share fully diluted. Growth...
- External links 2008-11-11
Additional Resources
- SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial
- ChinaBio Today submits: Beijing SL Pharmaceutical Co. Ltd. (SZSE: 002038) received SFDA approval to begin producing a hepatitis drug and a second SFDA authorization to begin clinical trials of drug for male infertility. Adefovir dipivoxil, the drug newly approved for marketing, is aimed at hepatitis B. It is currently...
- External links 2008-08-29
- China Nuokang Bio-Pharmaceutical Banks on a Favorable U.S. IPO
- ChinaBio Today submits: China Nuokang Bio-Pharmaceutical NKBP, a company focused on hematological and cardiovascular drugs, will offer 4.5 million ADSs on the Nasdaq exchange at a price between $10 and $12. The mid-point of the range represents a $50 million debut for Nuokang. The offering gives further evidence that...
- External links 2009-11-23
- Tinayin Reports Higher Revenue and Costs
- ChinaBio Today submits: Tianyin Pharmaceutical Co. TPI reported higher results for the first quarter of 2009 fiscal year. Revenues rose 33 % to $9.6 million, while net income increased at a slower pace, rising 11% to $1.8 million. However, because the number of shares outstanding almost doubled to 24.6...
- External links 2008-11-11
- Shengtai's Future in China Glucose Market Looks Sweet
- ChinaBio Today submits: Shengtai Pharmaceutical, Inc. (SGTI.OB) reported that its revenues climbed 76% in fiscal 2008 (ended June 30) to $91 million. Net Income was up 46% to $10.4 million. Shengtai makes and distributes pharmaceutical grade glucose products in China, as well as glucose and other products for the...
- External links 2008-10-02
- American Oriental Investors Unimpressed by Acquisition News
- ChinaBio Today submits: American Oriental Bioengineering, Inc. (NYSE: AOB) announced in its Q2 earnings announcement that it signed a letter of intent to acquire an unnamed China pharmaceutical distribution company. In the follow-up earnings call with analysts, management said that it would pay $110 million to purchase a company...
- External links 2008-08-13
- China Aoxing Fits New Stroke Drug into Product List
- ChinaBio Today submits: China Aoxing Pharmaceutical Company (CAXG.OB) was given a production license by the SFDA for Ligustrazine Phosphate Injection to treat ischemic cerebrovascular disease or ischemic stroke. Ligustrazine is a TCM substance that promotes blood circulation by dilating blood vessels and slowing coagulation. Although China Aoxing focuses on...
- External links 2008-12-21
- NeoStem Closes China Biopharma Acquisition to Boost Revenues
- ChinaBio Today submits: NeoStem, Inc. NBS announced it has closed its acquisition of China Biopharmaceuticals Holdings, Inc. (CHBP.OB). China Biopharma’s sole asset is a 51% stake in Suzhou Erye Pharmaceutical Co., a 50-year old pharmaceutical company that expects to generate $60 million in revenue and net income of $12...
- External links 2009-11-03
- Schering-Plough Takes Sole Possession of Its China JV
- ChinaBio Today submits: Schering-Plough Corporation SGP bought the 45% of its majority-owned China JV, Shanghai Schering-Plough Pharmaceutical, that it did not already own. Its former partners, Shanghai Pharmaceutical Group and Shanghai Pharmaceutical Industry Corporation, put the 45% stake up for sale in May, saying they wanted to streamline their...
- External links 2008-08-14
- Why Schering-Plough Bought Out Its China JV
- ChinaBio Today submits: Schering-Plough Corporation SGP bought the 45% of its majority-owned China JV, Shanghai Schering-Plough Pharmaceutical, that it did not already own. Its former partners, Shanghai Pharmaceutical Group and Shanghai Pharmaceutical Industry Corporation, put the 45% stake up for sale in May, saying they wanted to streamline their...
- External links 2008-08-15
- China Aoxing Alleviates Liquidity Needs with Sale of 5.2 Million Shares
- ChinaBio Today submits: China Aoxing Pharmaceutical Company (CAXG.OB) raised $5 million by selling 5.2 million shares at a price of $.95 each. The sale was made without an agent to fifteen institutional and other accredited investors. The selling price was a significant 34% discount to the previously reported closing...
- External links 2009-08-11
- Shengtai Pharma's Q2 Disappoints
- ChinaBio Today submits: Shengtai Pharmaceutical, Inc. (SGTI.OB) reported disappointing results for its Q2, which ended December 31, 2008. The company recorded $14.8 million in revenue, a drop of 41%, because of a large decline in sales of its cornstarch business. Sales of its other major product, pharmaceutical grade glucose,...
- External links 2009-02-15
- Simcere's Q1 Disappoints Investors
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR) disappointed investors with its Q1 financial report. The company announced revenues of $64.8 million, a 12% increase from the year earlier, but $5 million less than the average analyst forecast. Net income was $7.1 million, a 57% decrease from 2008. At...
- External links 2009-05-20
- BMP Sunstone Acquires Unique Constipation Drug
- ChinaBio Today submits: BMP Sunstone Corporation BJGP has agreed to acquire rights to the Runchang capsule, a liquid-filled hard capsule (LFHC), used to treat constipation. BMP Sunstone purchased the product from Darentang Pharmaceutical, a subsidiary of Tianjin Zhongxin Pharmaceutical Group Corporation Limited (SSE: 600329). The purchase, whose price was...
- External links 2008-11-21
- << Previous
- page 1 of 1
- Next >>
